A 71-year-old man is evaluated in the intensive care unit for new-onset tachypnea and pleu… — USMLE Step 3

A 71-year-old man is evaluated in the intensive care unit for new-onset tachypnea and pleuritic chest pain. He was admitted one week ago for severe community-acquired pneumonia requiring mechanical ventilation, from which he was successfully extubated yesterday. He has a history of severe chronic kidney disease with a baseline glomerular filtration rate of $12 \text{ mL/min/1.73 m}^2$ , not currently on dialysis. Vital signs today include a heart rate of $115\text{/min}$ , blood pressure $105/65\text{ mmHg}$ , and oxygen saturation of $90\%$ on room air. A computed tomography scan of the chest with intravenous contrast reveals a saddle pulmonary embolus. An intravenous anticoagulant relying on a highly sulfated glycosaminoglycan to bind an endogenous protease inhibitor is initiated. Four days later, routine laboratory studies reveal a platelet count of $85,000/\text{mm}^3$ , decreased from a baseline of $210,000/\text{mm}^3$ on admission. No new medications have been added, and physical examination is unremarkable except for mild bilateral lower extremity edema. A specific functional platelet assay returns positive. The initial anticoagulant is immediately discontinued. Based on the patient's underlying comorbidities, which of the following best describes the molecular mechanism of the most appropriate alternative therapy?

Reversible occupancy of the active catalytic site of factor IIaCevap
B
Indirect inhibition of factor Xa via antithrombin activation
C
Inhibition of the vitamin K epoxide reductase enzyme complex
D
Activation of antithrombin with a preferential inhibitory effect on factor Xa
E
Direct binding and inactivation of free and clot-bound factor Xa

Cevap

Reversible occupancy of the active catalytic site of factor IIa

The patient has developed Heparin-Induced Thrombocytopenia (HIT), evidenced by a significant drop in platelets following heparin exposure and a positive functional assay (serotonin release assay). Management requires immediate cessation of heparin and initiation of a non-heparin anticoagulant. Because the patient has severe renal impairment (GFR

12 \text{ mL/min/1.73 m}^2

), renally cleared agents such as fondaparinux or bivalirudin are contraindicated or require extreme caution. The most appropriate agent is argatroban, which is a hepatically cleared direct thrombin inhibitor. Its mechanism of action is the direct, reversible occupancy of the active catalytic site of factor IIa (thrombin).

Adım Adım Çözüm

Diagnose the patient's acute complication based on laboratory trends.

The patient developed a greater than 50% drop in platelet count (from 210,000 to 85,000) four days after starting unfractionated heparin, with a positive functional platelet assay, confirming Heparin-Induced Thrombocytopenia (HIT).

Recognizing HIT is critical because it requires immediate cessation of all heparin-containing products.

Determine the required intervention for the confirmed diagnosis.

Initiation of a non-heparin alternative anticoagulant.

HIT is a highly prothrombotic state. Discontinuing heparin is not enough; therapeutic anticoagulation must be maintained to treat the existing pulmonary embolus and prevent new thromboses.

Evaluate patient-specific comorbidities that influence drug selection.

The patient has severe chronic kidney disease with a baseline glomerular filtration rate of

12 \text{ mL/min/1.73 m}^2

Renal clearance is a major pathway for many anticoagulants (e.g., fondaparinux, bivalirudin, LMWH). Severe renal impairment significantly limits these options.

Select the optimal pharmacologic agent and identify its mechanism.

Argatroban is the optimal choice because it is hepatically cleared. Its mechanism of action is the reversible occupancy of the active catalytic site of factor IIa (thrombin).

Using a hepatically cleared agent avoids drug accumulation and bleeding toxicity in the setting of end-stage renal disease.

Anahtar Kavram

In patients with Heparin-Induced Thrombocytopenia (HIT) and concurrent severe renal impairment, hepatically cleared direct thrombin inhibitors (such as argatroban) are the anticoagulants of choice.

Tahmini Süre:2m 0s

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru